Adaptimmune Therapeutics PLC
ADAPYAdaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park.
Drugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
NYESO-1c259 T cells | Phase 2 | Ovarian Cancer | - | - |
Frequently asked questions
What is in Adaptimmune Therapeutics PLC's drug pipeline?→
CatalystAlert tracks 1 drug candidate in Adaptimmune Therapeutics PLC's (ADAPY) pipeline across Phase 2. Its lead program is NYESO-1c259 T cells (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Adaptimmune Therapeutics PLC's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Adaptimmune Therapeutics PLC (ADAPY) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ADAPY biotech catalysts?→
Add ADAPY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Adaptimmune Therapeutics PLC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.